


Omalizumab protects against early, late allergic responses

June 9 2017



(HealthDay)—For patients with a significant response to allergen

challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in *Allergy*.

Jordis Trischler, M.D., from the University Hospital Frankfurt in Germany, and colleagues determined the time course of the early (EAR) and late allergic reaction (LAR). Ten patients with a significant response to allergen challenge were treated with omalizumab. At week one, two, four, and eight, bronchial [allergen](#) provocations were repeated.

The researchers observed a significant reduction in EAR after four weeks (change in forced expiratory volume in one second [Δ FEV1], 28 versus 11 percent; P nitric oxide, 86 versus 53 ppb; P

"These results demonstrate the onset of protective effects earlier than previously determined, potentially improving seasonal utilization and combination with immunotherapy," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Omalizumab protects against early, late allergic responses (2017, June 9) retrieved 26 April 2024 from
<https://medicalxpress.com/news/2017-06-omalizumab-early-late-allergic-responses.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--